Pernix Therapeutics Announces Agreement to License a New FDA-Approved Product to Treat Gastroenterology Disease

Pernix Therapeutics Holdings, Inc.

, today announced it has entered into a license and supply agreement with a private company for a new FDA-approved prescription product to treat gastroenterology disease. Under the terms of the agreement, Pernix obtained exclusive marketing rights to this gastroenterology product in the United States.